CDSCO Biocompatibility Documentation Before Testing

What Should Be Ready Before ISO 10993 Testing?

The lab can run the test, but the manufacturer owns the biological evaluation logic. Before testing, the file should be able to answer the basic questions that determine whether the test plan is defensible.

• Device identity: final device name, model variants, patient-contacting components, and whether accessories need separate consideration.
• Contact classification: body contact type, contact duration, and whether the intended use creates edge cases that need explanation.
• Finished-device state: manufacturing process, cleaning, packaging, and sterilization state of the sample sent for testing.
• Material traceability: material grade, supplier information, additives, coatings, colorants, adhesives, and any formulation changes.
• Endpoint rationale: which ISO 10993 endpoints are applicable, which are justified by evidence, and which require testing.

Why Early Documentation Helps Indian Teams

Many Indian teams are building for more than one route: CDSCO licensing, export readiness, customer audits, tender documentation, FDA planning, or EU MDR planning. A weak test-first approach may solve one immediate question but leave the BEP, BER, TRA, or technical file fragmented later.

A better approach is to create a short biological evaluation plan before testing. It does not need to be long, but it should capture the device description, contact categorization, material information, evidence already available, test gaps, sample configuration, and acceptance logic. That plan makes it easier to brief the lab and easier to explain the final reports afterward.

Common Gaps Seen Before Testing

• Testing a non-final sample: the tested device does not match the sterilized, packaged, or production-intent device.
• Missing material change history: the file does not explain supplier, formulation, coating, or processing changes.
• Unclear endpoint selection: tests are chosen from a generic quote rather than the device contact category and risk profile.
• No TRA pathway: chemical characterization is planned, but there is no clear plan for toxicological interpretation.
• Report-to-file gap: lab reports exist, but the BER does not translate them into a reviewer-ready conclusion.

How to Brief the Lab Without Losing File Logic

The lab brief should not be only a request for a quote. It should tell the lab what device state is being tested, which contact category is assumed, which endpoints are expected, and whether the output needs to support only India documentation or a broader FDA/EU pathway later.

• Send the right sample description: include model, patient-contacting parts, production state, cleaning, packaging, and sterilization status.
• State the regulatory intention: explain whether the work is for CDSCO readiness, customer audit support, export planning, or a future 510(k)/EU MDR file.
• Ask for usable report detail: make sure the final report will identify the tested sample, method, extraction or exposure conditions, acceptance criteria, and deviations clearly.
• Plan the file conversion: decide who will convert the lab report into BEP, BER, TRA, and risk-management language after testing.

A Strong Pre-Testing File Should Include

• A one-page device and contact classification summary.
• A material and component table for patient-contacting parts.
• A sample-state note covering production, cleaning, packaging, and sterilization.
• A BEP-style endpoint matrix showing test, waiver, chemistry, literature, or rationale for each endpoint.
• A plan for converting lab reports into BER conclusions and, where needed, TRA conclusions.

When This Becomes a High-Intent Review

This is a high-value review when a team is about to spend money on testing, when a lab quotation looks generic, when a customer asks for ISO 10993 evidence, or when the device may later need US or EU documentation. A short review before testing can prevent an expensive second round of testing or a weak regulatory narrative.